IDM Pharma

Irvine, United States Founded: 1990 • Age: 36 yrs Acquired By Takeda
Cancer immunotherapies were developed by this US-based biotech firm.
Annual revenue - Latest available
Total funding - 1 rounds
Employees - Tracked headcount
Investors 3 Known backers
Products - Services tracked
Competitors 8 Brand Intelligence

About IDM Pharma

IDM Pharma is a company based in Irvine (United States) founded in 1990 was acquired by Takeda in May 2009. IDM Pharma operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.

  • Headquarter Irvine, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    $12.5 M (USD), Post-IPO

    Feb 21, 2007

  • Investors
  • Employee Count
    Not available
  • Acquired by
    Takeda

    (May 18, 2009)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of IDM Pharma

Investors in IDM Pharma

IDM Pharma has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals, Palo Alto Investors and Alta Partners.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Healthcare sector investments are managed through private equity strategies.
Locked Locked Locked
Venture capital firm focused on healthcare companies
Locked Locked Locked
Takeda Pharmaceuticals is engaged in developing innovative medicines globally.
Locked Locked Locked
Premium access

Investor details for IDM Pharma

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by IDM Pharma

Investments
Premium access

Investment portfolio details for IDM Pharma

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - IDM Pharma

Premium access

Detailed financials for IDM Pharma

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Idm Pharma Comparisons

IDM Pharma Primary company
Description
Cancer immunotherapies were developed by this US-based biote...
Location
Irvine, United States
Founded Year
1990
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for IDM Pharma

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of IDM Pharma

IDM Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
Locked Locked Locked
Small molecule therapeutics for cancer treatment are developed.
Locked Locked Locked
Cancer therapies are developed using selective pathway inhibitors.
Locked Locked Locked
MicroRNA-based therapeutics are developed for treating multiple diseases.
Locked Locked Locked
Therapeutics for cancer and rare diseases are developed.
Premium access

Detailed competitors of IDM Pharma

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Idm Pharma

Premium access

Complete news archive for IDM Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about IDM Pharma

IDM Pharma was founded in 1990 and raised its 1st funding round 17 years after it was founded.

IDM Pharma is headquartered in Irvine, United States. It is registered at Irvine, California, United States.

IDM Pharma was founded in 1990 and headquartered in Irvine, United States, within the biotechnology sector. Focus was placed on developing immunotherapies for cancer treatment. MEPACT (mifamurtide) was advanced for osteosarcoma and received approval in Europe prior to the 2007 acquisition by Takeda. Development of Bexidem for bladder cancer was subsequently halted. Operations centered on innovative therapeutic solutions in oncology.

IDM Pharma's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

IDM Pharma has 3 investors. Key investors include Takeda Pharmaceuticals, Palo Alto Investors, and Alta Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available